Neuren Pharmaceuticals(ASX:NEU)
Developing drug therapies forserious neurological disorders that emerge in early childhood &have no or limited treatment options
Highly successful US launchof DAYBUE™ (trofinetide) for Rett syndrome by partner Acadia
2023 net sales of US$177.2m;A$27m NEU royalties
1Q24 net sales US$75.9;A$11.6m royalties
2024 net sales guidance ofUS$370-420m; would earn NEU A$61-70m + A$77m sales milestone
Acadia advancingDAYBUE™ in Canada, Europe & Japan
NNZ-2591 in Phase 2 trialsfor four syndromes; 5x Rett market
All indications received FDAinvestigational new drug (IND) & orphan drug designation
Pitt Hopkins topline resultsexpected 2Q24, Angelman results expected 3Q24
Dec'23: PMS demonstratedsignificantly positive results, preparation underway for FDA end of Ph2 meeting
$243.1m cash as of 31 Mar'24
Market cap ~ $2.58B
- Forums
- ASX - By Stock
- NEU
- Neuren Media and Analyst Coverage
Neuren Media and Analyst Coverage, page-963
-
- There are more pages in this discussion • 374 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B |
Open | High | Low | Value | Volume |
$15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 696 | $15.59 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.67 | 6942 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 64 | 15.570 |
1 | 320 | 15.510 |
1 | 181 | 15.450 |
1 | 530 | 15.300 |
1 | 2500 | 15.250 |
Price($) | Vol. | No. |
---|---|---|
15.670 | 2340 | 1 |
15.800 | 20 | 1 |
15.810 | 316 | 1 |
15.850 | 800 | 1 |
15.900 | 500 | 1 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online